Pfizer raises stake in NRGN to 21%

Pfizer Inc. increased its commitment to Neurogen Corp. (NRGN), entering into a second agreement to develop central nervous system drugs. The new agreement, worth about $20 million, is to develop drugs based on GABA receptor subtypes to treat sleep disorders. The pharma company raised its equity position in NRGN to 21 percent through the purchase of